Table 2.
Clinical and nutrition related characteristics of people living with HIV/AIDS attending ART clinic (n = 422)
| Variables | Frequency | Percent |
|---|---|---|
| CD4 count | ||
| < 200 | 44 | 10 |
| 200–349 | 62 | 15 |
| 350–499 | 72 | 17 |
| ≥ 500 | 244 | 58 |
| WHO clinical stage | ||
| Stage I | 389 | 92 |
| Stage II | 15 | 3 |
| Stage III | 16 | 4 |
| Stage IV | 2 | 1 |
| Drug regimen | ||
| AZT-3TC-EFV | 68 | 16 |
| AZT-3TC-NVP | 80 | 19 |
| TDF-3TC-EFV | 217 | 51 |
| Others | 57 | 14 |
| Duration of treatment in months | ||
| < 24 | 126 | 30 |
| ≥ 24 | 296 | 70 |
| Chronic comorbidity | ||
| No | 375 | 89 |
| Yes | 47 | 11 |
| BMI | ||
| Underweight | 63 | 15 |
| Normal | 247 | 59 |
| Overweight | 112 | 26 |
| HHFIS | ||
| Secured | 107 | 25 |
| Unsecured | 315 | 75 |
AZT: Zidovudine; EFV: Efavirenz; NVP: Nevirapine; TDF: Tenofovir; 3 TC: Lamivudine